PGD2-IN-1 is an antagonist of DP extracted from patent WO 2006044732 A2, example 15 (d); has an IC 50 of 0.3 nM. In Vitro Prostaglandin D2 (PGD2) is a major inflammatory mediator implicated in asthma and allergic rhinitis. It is largely produced as the major cyclooxygenase metabolite upon allergen-provoked degranulation from mast cells. Blockage of PGD2 using DP antagonists has been shown to be effective at alleviating the symptoms of allergic rhinitis in multiple species and more specifically has been shown to inhibit the antigen-induced nasal congestion. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC50: 0.3 nM